FOI 5437- Cancer treatment

Date: 26 March 2020 to 26 March 2023

1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following:

                Paclitaxel

                Gemcitabine

                Osimertinib

                Carboplatin and Pemetrexed

                Cisplatin and Pemetrexed

                Pembrolizumab monotherapy

                Pembrolizumab in combination

                Atezolizumab

                Nivolumab

                Other active systemic anti-cancer therapy

2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?

2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:

                Cetuximab not in combination with FOLFIRIE or FOLOX

                Cetuximab in combination with FOLFIRI

                Cetuximab in combination with FOLFOX

                Panitumumab not in combination with FOLFIRI or FOLFOX

Panitumumab in combination with FOLFIRI

Panitumumab in combination with FOLFOX

Nivolumab

Aflibercept

Bevacizumab

Ramucirumab

Regorafenib

Sorafenib

Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)

3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?

3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?

4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?

                Locally advanced

                Recurrent metastatic

                Unable to split

4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)

                Carboplatin (only or in combination with 5-FU)

Cisplatin (only or in combination with 5-FU)

                Cetuximab with / without chemotherapy

                Cetuximab with radiotherapy

                Pembrolizumab monotherapy

                Pembrolizumab with chemotherapy

                Nivolumab

                Docetaxel (only or in combination with 5-FU)

                Fluorouracil (5-FU)

                Radiotherapy only

                Other

4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?           

4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:

                Cisplatin single agent

                Cisplatin in combination with another agent

                Carboplatin single agent

                Carboplatin in combination with another agent

                Nivolumab

                Pembrolizumab

                Atezolizumab

                Other active systemic anti-cancer therapy

5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?

5b – If so how many patients are currently taking part in clinical trials  / what is the name(s) of the trials ?

  • Request ID:
    FOI 5437
  • Category:
    Trust - Service Data
  • Response:

    1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following:

    Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated by the Trust. 

    However, we are able to confirm the number of patients diagnosed and had anti-cancer drug treatment (but not the specific drugs) at Medway NHS Foundation Trust within the last six months was:  15 NSCLC patients

    The Trust’s pharmacy department can confirm the number of patients currently on the below treatments, however, the reason for the treatments is not recorded against this and so we cannot confirm they are for the NSCLC patients noted above. 

                     Paclitaxel –0

                    Gemcitabine -0

                    Osimertinib - 0

                    Carboplatin and Pemetrexed - 9

                    Cisplatin and Pemetrexed - <5

                    Pembrolizumab monotherapy -15

                    Pembrolizumab in combination -<5

                    Atezolizumab - <5

                    Nivolumab-0

                    Other active systemic anti-cancer therapy 0

                  

    2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?- 0

     

    2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?-N/A

     

    3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following: As above, we regret we are unable to answer your request as this data is not collated by the Trust.  However, we can confirm the number of patients diagnosed and had anti-cancer drug treatment (but not the specific drugs) at Medway NHS Foundation Trust within the last six months was:  22 colorectal patients

    The Trust’s pharmacy department can conform the number of patients currently on the below treatments, however, the reason for the treatments is not recorded against this and so we cannot confirm they are for the colorectal patients noted above.

                Cetuximab not in combination with FOLFIRIE or FOLOX- 0

                Cetuximab in combination with FOLFIRI- 11

                Cetuximab in combination with FOLFOX- <5

                Panitumumab not in combination with FOLFIRI or FOLFOX- 0

    Panitumumab in combination with FOLFIRI- 0

    Panitumumab in combination with FOLFOX- 8

    Nivolumab- 0

    Aflibercept-0

    Bevacizumab- <5

    Ramucirumab-0

    Regorafenib- 0

    Sorafenib- 0

    Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)- 74

     

    3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?

    Yes, for the treatment of colorectal cancer patients

    3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ? <5 patient (Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer (NeoART)) and 18 patients (Short Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3 Groups (SCOT))

    4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?-

    Medway NHS Foundation Trust do not treat head and neck cancer at Medway Hospital.  All head and neck cancer patients are treated at Maidstone Hospital, therefore please can you redirect your request to the Maidstone and Tunbridge Wells NHS Trust.

     

    4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients?- n/a

                    Locally advanced

                    Recurrent metastatic

                    Unable to split-

     

    4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)- n/a

                    Carboplatin (only or in combination with 5-FU)

        Cisplatin (only or in combination with 5-FU)

                    Cetuximab with / without chemotherapy

                    Cetuximab with radiotherapy

                    Pembrolizumab monotherapy

                    Pembrolizumab with chemotherapy

                    Nivolumab

                    Docetaxel (only or in combination with 5-FU)

                    Fluorouracil (5-FU)

                    Radiotherapy only

                    Other-<5

     

    4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?-n/a  

          

    4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?-n/a

    5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:  As above, we regret we are unable to answer your request as this data is not collated by the Trust.  However, we can confirm the number of patients diagnosed and had anti-cancer drug treatment (but not the specific drugs) at Medway NHS Foundation Trust within the last six months was:  <5 urothelial carcinoma patients

    The Trust’s pharmacy department can conform the number of patients currently on the below treatments, however, the reason for the treatments is not recorded against this and so we cannot confirm they are for the urothelial carcinoma patients noted above.

                    Cisplatin single agent 0

                    Cisplatin in combination with another agent-<5

                    Carboplatin single agent -0

                    Carboplatin in combination with another agent -7

                    Nivolumab-<5

                    Pembrolizumab-0

                    Atezolizumab-<5

                    Other active systemic anti-cancer therapy <5

     

    5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ? Yes

    5b – If so how many patients are currently taking part in clinical trials  / what is the name(s) of the trials ?- <5 (A Prospective Randomised Phase III Study of Observation Versus Screening MRI And Pre-Emptive Treatment in Castrate Resistant Prostate Cancer Patients With Spinal Metastasis (PROMPTS)) and 22 patients (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE))